Table 1.
Clinicopathological description of the patients involved in this study.
| Premenopausal |
Postmenopausal |
|||
|---|---|---|---|---|
| Untreated |
Neoadjuvant chemotherapy |
Untreated |
Neoadjuvant chemotherapy |
|
| Characteristics | n (%) | n (%) | n (%) | n (%) |
| Age (years) Mean Median Range |
45.2 ± 1.2 48 27–54 |
45.1 ± 0.8 46 29–53 |
65.3 ± 0.9 64 57–78 |
65.3 ± 0.90 63 56–78 |
| Tumor histology Ductal Lobular Other |
39 (100%) 0 (0%) 0 (0%) |
63 (100%) 0 (0%) 0 (0%) |
44 (100%) 0 (0%) 0 (0%) |
52 (100%) 0 (0%) 0 (0%) |
| Molecular subtypes Luminal A Luminal B Her-2 Triple negative |
23 (59.0%) 10 (25.6%) 2 (5.1%) 4 (10.3%) |
34 (54.0%) 7 (11.1%) 18 (28.6%) 4 (6.3%) |
27 (61.4%) 6 (13.6%) 4 (9.1%) 7 (15.9%) |
27 (51.9%) 12 (23.1%) 0 (0%) 13 (25.0%) |
| Pathologic tumor size (cm) Mean ± SEM Median Range |
1.31 ± 0.09 1.20 0.5–3.1 |
3.02 ± 0.17 3.00 0.8–5.6 |
1.52 ± 0.14 1.30 0.8–5.0 |
3.36 ± 0.15 3.00 1.4–5.0 |
| Pathologic T classification 0 1 2 3 |
0 (0%) 35 (89.7%) 4 (10.3%) 0 (0%) |
0 (0%) 18 (28.6%) 40 (63.5%) 5 (7.9%) |
0 (0%) 40 (90.9%) 4 (9.1%) 0 (0%) |
0 (0%) 6 (11.5%) 43 (82.7%) 3 (5.8%) |
| Scarf-Bloom-Richardson grade I II III |
19 (48.7%) 20 (51.3%) 0 (0%) |
8 (12.7%) 55 (87.3%) 0 (0%) |
10 (22.7%) 34 (77.3%) 0 (0%) |
13 (25%) 39 (75%) 0 (0%) |
| Hormonal Status ER+ ER- PgR+ PgR- |
33 (84.6%) 6 (15.4%) 25 (64.1%) 14 (35.9%) |
41 (65.1%) 22 (34.9%) 41 (65.1%) 22 (34.9%) |
33 (75.0%) 11 (25.0%) 27 (61.4%) 17 (38.6%) |
36 (69.2%) 16 (30.8%) 33 (63.5%) 19 (36.5%) |
| HER-2/neu status Negative Positive |
29 (74.4%) 10 (25.6%) |
38 (60.3%) 25 (39.7%) |
34 (77.3%) 10 (22.7%) |
49 (94.2%) 3 (5.8%) |